2021 Partners
Ajinomoto BioPharma Services
Senior Partner
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. Ajinomoto Bio-Pharma Services is establishing itself as a premier, US-based provider for high-containment bioconjugate manufacturing, as well as fill and finish services for both Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC).
Heidelberg
Senior Partner
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
MilliporeSigma
Senior Partner
MilliporeSigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life saving therapies. We have the largest offering of products for formulations, actives and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts and stabilizers and from chromatography to TFF equipment, including single-use templates.
Partners
Abtis
Partner
AbTis is the bio-technology company which specializes in antibody-drug Conjugation technology and Solubilization of drugs through Micelle format with its own proprietary patents.
Our pipelines are designed to enhance the safety and efficacy of the current antibody drug conjugates by applying AbTis linker to the mAbs.Our technology is applicable to the native antibodies, commercial antibodies or novel antibodies under development as it requires no mutation or engineering to antibody itself.
AbTis is one of the leading bio-conjugation companies. We seek to create positive economic impact and long-term value, improved quality of life for the patients worldwide. AbTis was founded in 2016 by Professor Sang Jeon Chung, our Chairman and Chief Executive Officer, in 2017 it was seed funded $ 0.5 million and 2018 June, we secured $ 4.5 million private placement from 3 venture capital firms which are Stonebridge capital partners, K2 Investment and JX partners.
Abzena
Partner
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Affibody
Partner
Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has two clinical stage programs. The first is izokibep that targets autoimmune diseases. The second program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
Ardena
Partner
Ardena is a fully integrated pharmaceutical CDMO with a core focus on bringing molecules to the clinics. We offer drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with our customers to compile their regulatory dossier to fast-track their product towards compliance.
Ardena is uniquely positioned to offer quantitative bioanalysis from discovery research through GLP compliant preclinical assessments to late-stage clinical development. As such, we have supported numerous programs to assess the PK and immunogenicity of various ADCs using ligand binding assays as well as (hybrid) LC-MS/MS analysis.
AstraZeneca
BioPharma Translationsinstitut Dessau
Partner
BroadPharm
Partner
BSP
Partner
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Byondis
Partner
Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. Using its proprietary molecular concepts and technologies, Byondis generates next generation antibody-drug conjugates (ADCs). Its broad development portfolio includes the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985), whose pivotal Phase III TULIP® study reported positive topline results. Based in Nijmegen, the Netherlands, Byondis collaborates with leading biotechnology, pharmaceutical and academic research organizations. For more information, visit our website:
CARBOGEN AMCIS
Exhibitor
Collaborative Drug Discovery (CDD), Inc.
Partner
Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web interface.
CytomX
Partner
For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter.
Exelixis
Partner
Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our efforts have resulted in four approved products and we have partnered with leading pharmaceutical companies to make these available to patients worldwide. We are committed to prudently reinvesting in our business to maximize the potential of our pipeline, through both targeted business development and internal drug discovery – all to help cancer patients recover stronger and live longer.
Heraeus
Partner
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
ILC Dover
Partner
ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions. Based in Frederica, Delaware, we serve the pharmaceutical industry with single-use flexible powder solutions that facilitate safe and reliable performance and productivity in the lab. CMOs and CDMOs choose our solutions for powder transfers and containment over rigid stainless-steel systems, for the significant advantages they bring to chemical synthesis of HPAPI and OSD processing for final drug products.
IntoCell
Partner
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies. The company has developed a state of the art linker technology comprising of a novel self-immolative group based on OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker is designed to release phenolic payloads through intramolecular cyclization, mediated by ortho-hydroxyl group temporarily blocked by a triggering group. The technology has been extended to non-phenolics by introducing a phenolic spacer. The linker, with or without phenolic spacer, has been applied to full ADCs, which showed excellent dose dependent efficacy both in vitro and in vivo.
LegoChem Biosciences
Partner
LegoChem Biosiences is a clinical stage biotech with expertise in medicinal chemistry. It has several antibiotic programs for infectious disease with urgent needs and drugs in oncology and anti-fibrosis. It has extended its expertise to ADC and developed next-generation site-specific ADC platform with novel linker that improves stability of ADCs in blood circulation, effectively prevents premature drug release, efficiently facilitates liberation of the drug at targeted tumor cells and ultimately shows significant improved therapeutic index.
Levena BioPharma
Partner
At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
Lonza
Partner
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact adc@lonza.com or visit
MabPlex
Partner
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
MedChemExpress
Partner
Mersana Therapeutics
Partner
Mersana is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop novel ADCs with optimal efficacy and safety to meaningfully improve the lives of people fighting cancer. Mersana’s lead candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b being studied in UPLIFT, a single-arm registration strategy, in platinum-resistant ovarian cancer and in a Phase 1 study in NSCLC. XMT-1592, a Dolasynthen ADC targeting NaPi2b, is in a Phase 1 dose escalation study. Mersana’s preclinical programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, a STING-agonist ADC developed using its Immunosynthen platform.
NanoString
Partner
NanoString® is a leading provider of life science tools for translational research and diagnostics. Cited in over 4,000 peer-reviewed publications, the nCounter® Analysis System measures gene and protein expression to profile novel biomarkers. The company's GeoMx® Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
NOF
Partner
NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbates 20 and 80. Our cutting edge products include single molecule PEG linkers for ADCs “PIREBRIGHT Series” and SS-lipids for nucleic acid and gene delivery “COATSOME SS Series”.
Novasep
Partner
Novasep has been a leading contract service provider in the ADC arena for more than 10 years and provides unique services for the development, clinical supply and commercial manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody.
Our commitment to ADCs is underlined by the recent €11M investment in a stand-alone bioconjugation unit at our Le Mans site in France. The site has more than 30 years of experience in synthesis & purification of cytotoxics using industrial chromatography.
NJ Bio
Partner
NJ Bio is a quality CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates, and flow chemistry. The company is headquartered in the New Jersey Bioscience Center in North Brunswick, NJ, with additional chemistry facilities in Bristol, PA, and a satellite office in Cambridge, MA. NJ Bio is affiliated with Amar Chemistry in Mumbai, India, for continuous flow and high-pressure chemistry services as well as chemical process R&D and scale-up under a Blended FTE Services model. Contact info@njbio.com or visit our website
Piramal
Exhibitor
Pirimal Pharmaa Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Cliinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capibilityas an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
PPD
Exhibitor
PROVEO
Partner
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.
Quanta BioDesign
Exhibitor
Quanta BioDesign manufactures monodisperse, single molecular weight dPEG® reagents for the conjugation and modification of antibodies, proteins, peptides, and other biomolecules, as well as for surfaces and particles. SuperHydrophilic™ dPEG® reagents provide extreme water solubility, biocompatibility, and low nonspecific binding in research and commercial applications. Using patented and proprietary processes, we design, synthesize, and manufacture to large scale all of our dPEG® products in Plain City, OH, USA for use in life science, diagnostic and therapeutic applications.
Sartorius
Partner
The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.